Skip to content

Study · Randomized controlled trial · n = 35 · 2021

4 results

Effects of exenatide on microvascular reactivity in patients with type 2 diabetes and coronary artery disease: A randomized controlled study.

Östlund Papadogeorgos N, Kuhl J, Shore A, Kahan T, Jörneskog G, Kalani M

Microcirculation (New York, N.Y. : 1994)23 Nov 2020Cited by 1 (Europe PMC)

PMID33151597 (opens in a new tab)DOI10.1111/micc.12670 (opens in a new tab)PepBankPUB-33151597
Publisher pagePubMedAsk about this study
Jump to 4 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study4

4 results from studies that gave the peptide. 4 results from people.

  1. 01HumanRandomized controlled trialEfficacy outcome

    In patients with T2DM and CAD, the HbA1c reduction with exenatide versus conventional treatment was not significant.

    In plain wordsExenatide did not significantly reduce average blood sugar compared with conventional treatment in patients with diabetes and coronary disease.

    Peptide
    Exenatide (exendin-4)
    Outcome
    No significant changeHbA1c
    Study

    n = 35

    Comparator
    Conventional non-GLP-1-based therapy
    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    Dose not stated · 12 weeksAs given in this study (human).

    Measurements

    HbA1c
    63.5 mmol/mol
    exenatide baseline
    HbA1c
    60.7 mmol/mol
    exenatide follow-up

    Source sentences

    Summary
    At 12 weeks, patients on exenatide showed reductions in HbA1C (from 63.5 ± 13 to 60.7 ± 14 mmol/mol, p = .065),
    2 context sentences
    Summary · context
    as compared to the conventionally treated group.
    Summary · context
    Thirty-five patients with T2DM, CAD, and HbA1C 42-86 mmol/mol were randomized to treatment with exenatide or conventional non-GLP-1-based therapy for 12 weeks.
  2. 02HumanRandomized controlled trialEfficacy outcome

    In patients with T2DM and CAD, exenatide reduced body weight compared with conventional treatment.

    In plain wordsExenatide reduced body weight compared with conventional treatment in patients with diabetes and coronary disease.

    Peptide
    Exenatide (exendin-4)
    Outcome
    DecreaseBody weight
    Study

    n = 35

    Comparator
    Conventional non-GLP-1-based therapy
    Outcome group
    Body weight · Metabolic and weight
    Studied dose
    Dose not stated · 12 weeksAs given in this study (human).

    Measurements

    Weight
    92.6 kg
    exenatide baseline
    Weight
    89 kg
    exenatide follow-up

    Source sentences

    Summary
    body weight (from 92.6 ± 16 to 89 ± 16 kg, p < .001), and systolic blood pressure (from 141 ± 13 to 134 ± 16 mm Hg, p < .05) as compared to the conventionally treated group.
    1 context sentence
    Summary · context
    Thirty-five patients with T2DM, CAD, and HbA1C 42-86 mmol/mol were randomized to treatment with exenatide or conventional non-GLP-1-based therapy for 12 weeks.
  3. 03HumanRandomized controlled trialEfficacy outcome

    In patients with T2DM and CAD, exenatide reduced systolic blood pressure compared with conventional treatment.

    In plain wordsExenatide reduced systolic blood pressure compared with conventional treatment in patients with diabetes and coronary disease.

    Peptide
    Exenatide (exendin-4)
    Outcome
    DecreaseSystolic blood pressure
    Study

    n = 35

    Comparator
    Conventional non-GLP-1-based therapy
    Outcome group
    Blood pressure · Cardiovascular
    Studied dose
    Dose not stated · 12 weeksAs given in this study (human).

    Measurements

    Systolic blood pressure
    141 mm Hg
    exenatide baseline
    Systolic blood pressure
    134 mm Hg
    exenatide follow-up

    Source sentences

    Summary
    systolic blood pressure (from 141 ± 13 to 134 ± 16 mm Hg, p < .05) as compared to the conventionally treated group.
    1 context sentence
    Summary · context
    Thirty-five patients with T2DM, CAD, and HbA1C 42-86 mmol/mol were randomized to treatment with exenatide or conventional non-GLP-1-based therapy for 12 weeks.
  4. 04HumanRandomized controlled trialEfficacy outcome

    In patients with T2DM and CAD, skin microvascular function showed no significant between-group or within-group change with exenatide.

    In plain wordsSkin small-vessel function did not significantly change with exenatide versus conventional treatment or from baseline.

    Peptide
    Exenatide (exendin-4)
    Outcome
    No significant changeSkin microvascular function
    Study

    n = 35

    Comparator
    Conventional non-GLP-1-based therapy
    Outcome group
    Vascular function · Cardiovascular
    Studied dose
    Dose not stated · 12 weeksAs given in this study (human).

    Source sentences

    Summary
    There were no significant changes in skin microvascular function between or within the two groups at follow-up.
    1 context sentence
    Summary · context
    Thirty-five patients with T2DM, CAD, and HbA1C 42-86 mmol/mol were randomized to treatment with exenatide or conventional non-GLP-1-based therapy for 12 weeks.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    22 Oct 2026, 02:26 UTC

    Study results updated

  2. Version 1

    21 Oct 2026, 18:59 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.